ASTX727 and Donor Lymphocyte Infusions After Allogenic Stem Cell Transplantation in Very High Risk MDS or AML Patients

NCT04857645 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

57

Enrollment

OTHER

Sponsor class

Conditions

MDS
AML

Interventions

DRUG: ASTX727
OTHER: Donor Lymphocyte Infusions

Sponsor

Groupe Francophone des Myelodysplasies

Collaborators

[object Object]